about
Profile of tivozanib and its potential for the treatment of advanced renal cell carcinomaInterferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic reviewRationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinomaThe role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.TRAIL and interferon-alpha act synergistically to induce renal cell carcinoma apoptosis.IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosisNox4 is critical for hypoxia-inducible factor 2-alpha transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma.Current status of targeted therapy for advanced renal cell carcinomaRetrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival.The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy.Treatment, Outcome and Prognostic Factors in Renal Cell Carcinoma - A Single Center Study (2000-2010).The von Hippel-Lindau gene: turning discovery into therapy.VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.Renal cell carcinoma: how to hit the targets?Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma.New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib.Possible immunotherapeutic potentiation with D-fraction in prostate cancer cells.Additively enhanced antiproliferative effect of interferon combined with proanthocyanidin on bladder cancer cells.
P2860
Q26827319-EA4F17A8-B828-4B3C-BC5B-B1704BD83155Q33591376-3B243AAB-E438-4FFE-8BAC-C1412F1B8D20Q34064359-1AF2340C-47D1-41D3-A94D-C4ADAB76B8C8Q34235680-5BA3CE3E-1B5F-488E-9038-987E3D59B98FQ34235703-86AA3394-E5CA-45FF-8806-EC0CEF5DC052Q34598755-A33FEC1B-7E0E-40B4-B521-609644F7A626Q34603364-5D86821B-AB5F-4F1C-B56E-3CBFC2310F4BQ35903850-8ED9484D-B845-4FA1-8E31-CE2FC9E492C7Q36153108-B18D97BF-968D-446D-BF36-86A3F5ADFDEDQ36204010-EDD3780B-E0F4-42CC-BE04-3A6263517363Q37012044-D0198F01-375E-4ADD-9124-7838F6AC3CEBQ37272653-0CE25B13-F5B7-41FA-85AC-CDC490FBCDC1Q37393004-59543B03-85BC-49A7-8F34-57485C60C7B0Q37481890-E261FF64-5E91-4584-B903-BF0781E3FF2AQ37640802-04B93B50-E3B4-4446-8E78-A75EAEC93855Q37697141-B0BE8B94-73AF-42F9-8026-C1767A7CA64EQ37711561-7A0605AA-2841-48A2-B58B-C76594177E81Q37774569-10E36B40-6E52-4FAF-8079-A6B50F9790FCQ37806966-E3FB13C8-179E-4282-886C-B4CAE5171491Q39908976-10565ECE-F76C-4771-8D48-30D8F22A6856Q41891215-1473968A-114B-4AC9-B46D-81CC83FAA37D
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cytokine therapy for metastatic renal cell carcinoma.
@ast
Cytokine therapy for metastatic renal cell carcinoma.
@en
Cytokine therapy for metastatic renal cell carcinoma.
@nl
type
label
Cytokine therapy for metastatic renal cell carcinoma.
@ast
Cytokine therapy for metastatic renal cell carcinoma.
@en
Cytokine therapy for metastatic renal cell carcinoma.
@nl
prefLabel
Cytokine therapy for metastatic renal cell carcinoma.
@ast
Cytokine therapy for metastatic renal cell carcinoma.
@en
Cytokine therapy for metastatic renal cell carcinoma.
@nl
P1433
P1476
Cytokine therapy for metastatic renal cell carcinoma.
@en
P2093
Bukowski RM
P304
P577
2001-05-01T00:00:00Z